openPR Logo
Press release

Follicular Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharm

01-08-2025 03:17 PM CET | Health & Medicine

Press release from: DelveInsight

Follicular Lymphoma Pipeline Insights

Follicular Lymphoma Pipeline Insights

Follicular Lymphoma Pipeline constitutes 50+ key companies continuously working towards developing 55+ Follicular Lymphoma treatment therapies, analyzes DelveInsight.

Follicular Lymphoma Overview:

Follicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma (NHL), accounting for 20-30% of all NHL cases. While not typically curable, FL is often managed as a chronic condition, with patients living for many years post-diagnosis. FL originates from germinal center B-cells and is characterized by abnormal proliferation of malignant B-cells, leading to lymph node enlargement, spleen or bone marrow involvement, and potential spread to other tissues and organs.

The hallmark genetic mutation in FL is the translocation t(14;18)(q32;q21), causing overexpression of BCL2, an anti-apoptotic protein. About 5% of cases involve deregulated BCL6, critical for germinal center formation and transcription regulation. Other implicated genes include those related to cell cycle arrest, such as p21 and p16.

Symptoms and Diagnosis
Common symptoms include swollen lymph nodes in the neck, underarms, abdomen, or groin, fatigue, night sweats, weight loss, and shortness of breath. Many patients remain asymptomatic at diagnosis. Evaluation involves clinical history, physical exams, laboratory tests (e.g., complete blood count, lactate dehydrogenase levels), and imaging (CT, MRI, FDG PET/CT). Diagnosis typically requires lymph node biopsy with morphological assessment, flow cytometry, and sometimes genetic testing.

Management
Treatment varies based on disease stage and patient preferences. Options include:
- Radiation Therapy (RT): For early-stage disease.
- Immunochemotherapy: Common regimens are Rituximab combined with chemotherapy (R-CHOP, CVP, or bendamustine).
- Single-Agent Rituximab: For select cases.
- Observation: For asymptomatic patients with indolent disease until progression.
- Combination Approaches: Immunochemotherapy plus RT in advanced stages.

Treatment decisions depend on disease stage, physician recommendation, and patient preference, emphasizing individualized care.

Request for a detailed insights report on Follicular Lymphoma pipeline insights @ https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Follicular Lymphoma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Follicular Lymphoma Therapeutics Market.

Key Takeaways from the Follicular Lymphoma Pipeline Report

DelveInsight's Follicular Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Follicular Lymphoma treatment.
In August 2024, the company plans to submit a supplemental Biologics License Application (sBLA) for tafasitamab by the end of the year. This application targets the treatment of patients with follicular lymphoma (FL) who have not responded to at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy, based on positive Phase III trial results.
In June 2024, a consortium led by Eugene Private Equity and Korea Development Bank Private Equity announced the acquisition of an 80% stake in South Korean vaccine manufacturer Boryung Biopharma Co. for 320 billion won (approximately USD 231 million).
In February 2024, Incyte revealed it had entered into an asset purchase agreement with MorphoSys AG, granting Incyte exclusive global rights to tafasitamab. Following this agreement, Incyte will assume full responsibility for U.S. commercialization and clinical development, with MorphoSys no longer eligible for milestone payments, profit shares, or royalty payments.
Key Follicular Lymphoma companies such as Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, and others are evaluating new drugs for Follicular Lymphoma to improve the treatment landscape.
Promising Follicular Lymphoma pipeline therapies in various stages of development include MIL62, AZD0486, Abexinostat, ABBV-319, NX-2127, and others.

Follicular Lymphoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Follicular Lymphoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Follicular Lymphoma market.

Download our free sample page report on Follicular Lymphoma pipeline insights @ https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Follicular Lymphoma Emerging Drugs

MIL62: MAB WORKS
AZD0486: AstraZeneca
Abexinostat: Xynomic Pharmaceuticals
ABBV-319: AbbVie
NX-2127: Nurix Therapeutics, Inc.

Follicular Lymphoma Companies

Over 50 prominent companies are actively working on developing therapies for Follicular Lymphoma. Among these, MAB WORKS and AstraZeneca have drug candidates in the most advanced stage of development, specifically Phase III trials.

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Follicular Lymphoma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Follicular Lymphoma Therapies and Key Companies: Follicular Lymphoma Clinical Trials and advancements @ https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Follicular Lymphoma Pipeline Therapeutic Assessment
• Follicular Lymphoma Assessment by Product Type
• Follicular Lymphoma By Stage
• Follicular Lymphoma Assessment by Route of Administration
• Follicular Lymphoma Assessment by Molecule Type

Download Follicular Lymphoma Sample report to know in detail about the Follicular Lymphoma treatment market @ Follicular Lymphoma Therapeutic Assessment @ https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Follicular Lymphoma Current Treatment Patterns
4. Follicular Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Follicular Lymphoma Late-Stage Products (Phase-III)
7. Follicular Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Follicular Lymphoma Discontinued Products
13. Follicular Lymphoma Product Profiles
14. Follicular Lymphoma Key Companies
15. Follicular Lymphoma Key Products
16. Dormant and Discontinued Products
17. Follicular Lymphoma Unmet Needs
18. Follicular Lymphoma Future Perspectives
19. Follicular Lymphoma Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Follicular Lymphoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Follicular Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharm here

News-ID: 3807923 • Views:

More Releases from DelveInsight

Lewy Body Disease Clinical Trials Analysis 2025: α-synuclein Immunotherapies, Neuroinflammatory Modulators, and Symptomatic Agents Drive a Diversified Pipeline | DelveInsight
Lewy Body Disease Clinical Trials Analysis 2025: α-synuclein Immunotherapies, N …
DelveInsight's "Lewy Body Disease - Clinical Trials Analysis, 2025" highlights a rapidly evolving trial landscape targeting the underlying biology and complex symptomatology of dementia with Lewy bodies (DLB) and related α-synucleinopathies. Given the condition's dual burden of cognitive decline and parkinsonism, trials increasingly integrate biomarker-driven patient selection with multidomain endpoints spanning cognition, daily function, neuropsychiatric symptoms, and quality of life. Late-stage and registration-enabling programs include α-synuclein immunotherapies and clearance enhancers (e.g.,
Chronic Pulmonary Infections Clinical Trials Analysis 2025: Inhaled Antimicrobials, NTM-Targeted Regimens, and Host-Directed Strategies Aim to Suppress Pathogens and Preserve Lung Function | DelveInsight
Chronic Pulmonary Infections Clinical Trials Analysis 2025: Inhaled Antimicrobia …
DelveInsight's "Chronic Pulmonary Infections - Clinical Trials Analysis, 2025" outlines an active and heterogeneous development landscape addressing long-standing airway infections (non-CF bronchiectasis, chronic Pseudomonas infection, and pulmonary nontuberculous mycobacteria [NTM]). Trials prioritize durable microbiological suppression, exacerbation reduction, and functional outcomes (lung function, exacerbation rate, quality of life) because persistent infection drives progressive decline and healthcare use. Late-stage and registration-enabling programs focus on inhaled and targeted antimicrobials (liposomal amikacin/ALIS and novel inhaled
Chronic Pulmonary Infections Clinical Trials Analysis 2025: Inhaled Antimicrobials, NTM-Targeted Regimens, and Host-Directed Strategies Aim to Suppress Pathogens and Preserve Lung Function | DelveInsight
Chronic Pulmonary Infections Clinical Trials Analysis 2025: Inhaled Antimicrobia …
DelveInsight's "Chronic Pulmonary Infections - Clinical Trials Analysis, 2025" outlines an active and heterogeneous development landscape addressing long-standing airway infections (non-CF bronchiectasis, chronic Pseudomonas infection, and pulmonary nontuberculous mycobacteria [NTM]). Trials prioritize durable microbiological suppression, exacerbation reduction, and functional outcomes (lung function, exacerbation rate, quality of life) because persistent infection drives progressive decline and healthcare use. Late-stage and registration-enabling programs focus on inhaled and targeted antimicrobials (liposomal amikacin/ALIS and novel inhaled
ATTR Amyloidosis Clinical Trials Analysis 2025: RNA-silencing, TTR Stabilizers, and One-time Gene-Editing Approaches Aim to Halt Amyloid Deposition and Restore Organ Function | DelveInsight
ATTR Amyloidosis Clinical Trials Analysis 2025: RNA-silencing, TTR Stabilizers, …
DelveInsight's "ATTR Amyloidosis - Clinical Trials Analysis, 2025" describes a crowded, fast-moving development landscape focused on two complementary goals: (1) suppress hepatic TTR production or stabilize circulating TTR to stop further amyloid deposition, and (2) reverse organ dysfunction (cardiac and neuropathic) and improve survival, functional capacity, and quality of life. Ongoing programs span TTR stabilizers, RNA-silencing/ASO agents for transthyretin reduction, repeat-dose oligonucleotides, and emerging in-vivo gene-editing candidates that could offer

All 5 Releases


More Releases for Follicular

Key Trends Reshaping the Follicular Lymphoma Treatment Market: Technological Adv …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Follicular Lymphoma Treatment Market Size Growth Forecast: What to Expect by 2025? In recent years, there has been robust growth in the size of the follicular lymphoma treatment market. The market is projected to expand from $3.05 billion in 2024 to $3.28 billion in 2025, with a compound annual
Follicular Lymphoma Market to Reach USD 6.74 Billion by 2034
Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma (NHL), accounting for roughly 20-30% of NHL cases worldwide. It is generally an indolent (slow-growing) B-cell malignancy, but it can transform into aggressive lymphoma in some patients. With advancements in immunotherapy, monoclonal antibodies, and targeted therapies, treatment outcomes have improved, offering patients longer remission periods and better quality of life. Download Full PDF Sample Copy of Market Report @
Follicular Lymphoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Follicular Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways
Follicular Lymphoma Pipeline Insights Report 2024
DelveInsight's, "Follicular Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways
Global Follicular Lymphoma Treatment Industry Opportunities, Analysis & Forecast …
Dhirtek Business Research and Consulting most recent study on the follicular lymphoma treatment market provides a comprehensive view of the entire market. The research report delves deeply into the global follicular lymphoma treatment market's drivers and restraints. Analysts have extensively researched the global follicular lymphoma treatment market's milestones and the current trends that are expected to determine its future. Primary and secondary research methods were used to create an in-depth
Follicular Unit Extraction (FUE) Systems Market 2021 | Detailed Report
ReportsnReports publishes the report titled Follicular Unit Extraction (FUE) Systems that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes the report a valuable asset for stakeholders to make robust decisions. This report also provides an in-depth overview of product type, specification, technology, and production analysis considering vital